Hope for kids with rare, devastating kidney disease

NCT ID NCT04580420

Recruiting now Disease control Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called DCR-PHXC in children with a rare genetic disease called Primary Hyperoxaluria Type 1 (PH1) who have severe kidney damage or are on dialysis. The main goals are to see if the drug is safe and if it can lower harmful substances in the blood that damage the kidneys. Participants will receive the drug for an initial 6 months, with the option to continue for up to 5 more years if it helps.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Trial Site
ACTIVE_NOT_RECRUITING

San Francisco, California, 94143, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02115, United States
Clinical Trial Site
RECRUITING

Rochester, Minnesota, 55905, United States

Contact
Clinical Trial Site
ACTIVE_NOT_RECRUITING

New York, New York, 10016, United States
Clinical Trial Site
WITHDRAWN

Bron, 69677, France
Clinical Trial Site
WITHDRAWN

Paris, 75019, France
Clinical Trial Site
RECRUITING

Bonn, 53127, Germany

Contact
Clinical Trial Site
WITHDRAWN

Heidelberg, 69120, Germany
Clinical Trial Site
WITHDRAWN

Roma, 00165, Italy
Clinical Trial Site
RECRUITING

Beirut, 00001, Lebanon

Contact
Clinical Trial Site
WITHDRAWN

Casablanca, 2025, Morocco
Clinical Trial Site
WITHDRAWN

Oradea, 410469, Romania
Clinical Trial Site
WITHDRAWN

Oradea, 410562, Romania
Clinical Trial Site
RECRUITING

Barcelona, 08035, Spain

Contact
Clinical Trial Site
WITHDRAWN

Santa Cruz de Tenerife, 38320, Spain
Clinical Trial Site
RECRUITING

Dubai, +971, United Arab Emirates

Contact
Clinical Trial Site
WITHDRAWN

London, NWG 2Q3, United Kingdom
Clinical Trial Site
RECRUITING

London, WC1N3JH, United Kingdom

Contact

Conditions

Explore the condition pages connected to this study.

END STAGE RENAL DISEASE PRIMARY HYPEROXALURIA TYPE 1